FTY720 treatment decreased tumor growth in a xenograft model of hepatoblastoma. by Laura L. Stafman (6577184)

“…When tumors reached an average of 150 mm³, mice were randomized to receive vehicle (ORA-Plus, 50 μL, n = 7) or FTY720 (10 mg/kg body weight/day in ORA-Plus, 50 μL, n = 7) by oral gavage for 16 days. …”

Inhibition of PKCδ causes a decrease in viral replication. by Brian D. Carey (6092747)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

VGB decreased activation of the mTOR pathway in vivo. by Bo Zhang (6559)

The decrease in blood flow disrupts CV pruning. by Lin Wen (557398)

Hyperalgesia was assessed by a decrease in paw withdrawal threshold (PWT_50%) in a model of mild heat injury (MHI). by Manuel P. Pereira (417488)

Capzb2 coimmunoprecipitates with βIII-tubulin in brain lysates and decreases tubulin polymerization in vitro. by David A. Davis (239142)

“…<p>(A) In order to avoid overlap of the heavy chain signal (∼50 kDa) with the βIII-tubulin signal (∼55 kDa) in the immunoprecipitation using the Capzb2 monoclonal antibody (mAb), the antibody was coupled to the protein G/A beads through cross-linking. βIII-tubulin and Capzb2 signals were each detected following immunoprecipitation from brain lysate with both βIII-tubulin rabbit antibody (rAb)-coupled beads and Capzb2 mAb-coupled beads. …”

miR-153 was decreased in osteosarcoma tissues and cell line. by Guangfeng Niu (707090)

Decreased numbers of motor neurons in Tc1 and Dp(16)1Yey mice. by Sheona Watson-Scales (586942)

Antitumor Activity of FGFR Inhibitor as a Result of a Decrease in the Breast TIC Subpopulation In Vivo. by Sungeun Kim (105743)

Decrease in proliferation after ENU-exposure as decrease in BrdU immunostaining. by Vivian Capilla-Gonzalez (336046)

“…<p>Micrograph of the BrdU+ cells immunolabeled with DAB showed a decrease in the proliferation in the SVZ (B) and DG (D) of treated animals, compared with control group (A and C, respectively). …”

Quercetin decreased mitochondrial- and intercellular ROS. by Takaya Sugawara (9338487)

Galiellalactone decreases the proportion of ALDH+ prostate cancer cells in vitro and the ALDH1A1 expression in vivo. by Rebecka Hellsten (348459)

“…The proportion of ALDH+ cells is expressed as mean ± SEM (n = 2–4). The proportion of ALDH+ DU145 cells were significantly decreased by galiellalactone at the concentrations 10 µM (p = 0.0060), 25 µM (p = 0,0013) and 50 µM galiellalactone (p<0,0001). …”

Gradual decreases in tyrosinase expression detected by Western blotting. by Shuji Nakamura (230936)

Decreased levels of ubiquitinated proteins in U87MG cells that express PTEN. by Rajaa Errafiy (497050)

Diclofenac decreases angiogenesis. by Nina Mayorek (241888)

Increased expression of Fz5 receptor matched with a decrease in NeuN immunoreactivity at 16w. by Carlos González-Fernández (2794207)

Comparison of the decrease of CFU in CSF and blood between treatment groups within the first 6 h after treatment. by Luca G. Valente (12463057)

Resveratrol decreases cell proliferation in a time and dose dependent manner. by Mehtap Kilic Eren (591048)

Subjects:

Stx16-depleted MDCK monolayer show decreased transepithelial resistance (TER). by Jae-Joon Jung (139625)